Welcome to the OncoDaily Medical Journal, a peer-reviewed, open-access publication committed to advancing clinical and scientific knowledge in oncology. Our mission is to accelerate the dissemination of impactful research, expert perspectives, and real-world solutions that improve cancer care globally.
We encourage both seasoned and emerging voices in oncology to submit their work. All submissions undergo rigorous editorial screening and peer review.
Manuscript Types Accepted
Original research: up to 4000 words, up to 300 words abstract, up to 8 tables/figures, and up to 100 references. structured format including sections like introduction, methods, results, discussion, and references.
Narrative review / systematic review/meta-analysis: up to 5000 words, up to 300 words abstract, up to 5 tables/figures, up to 120 references.
Editorial: no word limit, abstract not specified, tables/figures not specified, references not specified.
Correspondence: up to 500 words, abstract not required, 1 table/figure, up to 5 references. letters to the editor discussing case studies or responses to published articles. subject to peer review.
Short communication: up to 2000 words, up to 200 words abstract, up to 4 tables/figures, up to 20 references. brief reports on original studies or case series, potentially including negative results.
Special communication: up to 1500 words, up to 200 words abstract, up to 2 tables/figures, and up to 20 references. evidence-based approaches to significant issues. often by invitation; non-invited submissions need editor approval.
Diagnostic test interpretation: up to 1500 words, up to 200 words abstract, up to 2 tables/figures, and up to 20 references. guidance on the application of new diagnostic or prognostic tests.
Clinical evidence to practice: up to 1500 words, up to 150 words abstract, up to 2 tables/figures, and up to 20 references. summarizes recent clinical trials with a focus on their application in practice.
Pro/con debates: up to 1000 words, abstract not specified, tables/figures not specified, up to 50 references. presentation of opposing viewpoints on a significant issue.
Case reports/brief reports: up to 1500 words, up to 275 words abstract, up to 3 tables/figures, up to 20 references. reports on unique clinical cases or small series, including significant individual observations.
Commentaries: up to 2000 words, abstract not structured, up to 1 table/figure, up to 20 references. perspectives on topical issues in oncology, often highlighting current research or clinical challenges.
Oncology grand rounds: up to 2500 words, abstract not specified, up to 1 table/figure, references not specified. case-based presentations detailing patient management, focusing on complex cases.
Special articles: up to 4000 words, abstract not structured, up to 6 tables/figures, references not specified. articles including guidelines, consensus meeting summaries, or other significant scholarly communications.
Statistics in oncology: up to 4000 words, abstract not specified, up to 6 tables/figures, up to 150 references. articles presenting new methods, controversies, or reviews relevant to biostatistics and oncology research.
60 questions/answers: no word limit, no abstract limit, up to 3 tables/figures, references not specified. a detailed question-and-answer format covering comprehensive topics within the field, aimed at educating readers on complex issues.
Hypothesis article: up to 3000 words, up to 250 words abstract, up to 4 tables/figures, up to 50 references. proposes a new hypothesis or theoretical framework. supported by preliminary data, logical reasoning, or literature.
News: up to 500 words, abstract not required, 1 table/figure, no references. highlights on news/events, reviews of books, films, plays, and summaries of meetings or conferences.
Submission Process
The OncoDaily Medical Journal uses a structured, form-based submission system designed to streamline the editorial process and reduce delays. Authors are asked to carefully follow the steps below to ensure their submission is complete and ready for review. Submission Form
Before you begin, please ensure your submission is complete. At a minimum, you will need:
– A manuscript in Word format (.doc or .docx), prepared according to our author guidelines.
– Cover Letter – A brief statement outlining the importance of the work and confirming originality.
– An abstract (max 300 words) and 3–6 keywords.
– Full author names and affiliations, including the corresponding author’s email and ORCID iD (recommended).
– Any relevant figures (submitted as separate high-resolution image files) and supplementary materials.
– A conflict of interest statement, funding information, and ethics approval or trial registration number, where applicable.
References must be formatted in Vancouver system.
Authors’ Responsibilities
Authors must submit original work that has NOT been published elsewhere. Proper citation of prior work is mandatory. Plagiarism (including self-plagiarism) is grounds for rejection or retraction.
Authorship Criteria: All listed authors must meet the ICMJE criteria:
– Substantial contributions to the research
– Drafting or critical revision
– Final approval of the version to be published
– Agreement to be accountable for all aspects of the work
– Disclosure of Conflicts of Interest: All financial and non-financial conflicts must be disclosed at submission. Failure to disclose relevant relationships may result in rejection or retraction.
– Data Integrity and Availability: Authors must ensure accuracy in data reporting and maintain data records for at least 10 years. Data must be made available upon validation request.
– Ethical Compliance for Human and Animal Studies:
– Human research must follow the Declaration of Helsinki, with ethical committee approval and informed consent documentation.
– Studies involving human biospecimens must specify consent protocols and institutional oversight.
– Animal research must comply with institutional/national guidelines and the ARRIVE guidelines. Authors must report ethical approval and protocol numbers.
– Patient Privacy and Informed Consent: Identifiable patient information and images require signed consent for publication. Privacy rights must be preserved at all times.
– Redundant or Duplicate Submission: Authors must not submit the same work to more than one journal. Translations or republications require transparent disclosure and permission from the original publishers.
Ethical Oversight
Ethical concerns brought to the journal’s attention—whether during peer review or post-publication—will be reviewed by the Editor-in-Chief and/or the ethics committee.
ODMJ commits to:
– Investigating allegations promptly and confidentially
– Communicating with relevant authors, reviewers, and institutions
– Taking appropriate corrective actions (e.g., retraction, expression of concern)
– Using COPE’s flowcharts and best practices as procedural guides
– The journal may refer complex cases to independent ethics bodies or legal counsel.
You will also be invited to suggest up to three peer reviewers, providing their names, affiliations, and email addresses. These individuals must not have any recent or direct professional relationships with the authors.
Once submitted, you will receive a confirmation email stating that your manuscript has been received and is undergoing initial editorial screening. This phase typically takes 5-7 working days, during which our editors assess the submission for completeness, relevance, and adherence to formatting guidelines. If the manuscript passes screening, it will be sent for external double-blind peer review, meaning that both the reviewers and the authors remain anonymous to one another throughout the review process.
If revisions are requested, you will be asked to submit a revised manuscript with a point-by-point response to reviewer comments. Following acceptance, the article will be professionally copyedited and formatted, assigned a DOI, and published online. Most accepted articles are published within 5–7 days of final approval.
All published work benefits from dissemination through the wider OncoDaily network.
For questions or pre-submission inquiries, please contact us at [email protected].